Content in this topic
COVID-19 won’t be the last virus to threaten the global population, but new disease surveillance tech could catch the next outbreak before it even starts.
The U.K. is funding a $44 million human challenge trial for COVID-19 during which healthy volunteers will be deliberately exposed to the coronavirus.
Patients are experiencing sudden hearing loss from COVID-19, but if caught early enough, doctors can prevent the problem from becoming permanent.
The coronavirus can survive on surfaces, including money, for up to 28 days. But does that change what you need to do to avoid catching COVID-19?
Post-COVID-19 clinics are helping coronavirus survivors cope with lingering symptoms while helping researchers better understand the disease.
A newly formed network of labs will make it easier to compare COVID-19 vaccines by testing them all in exactly the same way, using the exact same supplies.
Rather than feeling sick, some people may be getting pain relief from coronavirus — a discovery that could impact both the pandemic and the opioid epidemic.
Adjuvants create a better vaccine immune response, but they also cause inflammation. A peptide may help curb their side effects while improving protection.
A nasal spray vaccine for COVID-19 that contains a live coronavirus genetically engineered to replicate more slowly is nearing human trials.